<DOC>
	<DOCNO>NCT01038037</DOCNO>
	<brief_summary>The purpose study determine whether addition panitumumab standard chemotherapy first-line treatment advance Non Small Cell Lung Cancer improve treatment outcome . Patients select base triple mutational status .</brief_summary>
	<brief_title>First-Line Chemotherapy Panitumumab Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Advanced NSCLC hold poor prognosis moderate response rate standard chemotherapy . The standard first-line treatment advance NSCLC platinum base combination chemotherapy . The response rate less 30 % substantial amount patient experience unnecessary toxicity term e.g . nausea , vomit , neuropathy considerable risk renal toxicity . The median progression free survival 3-4 month consequently , median overall survival less one year ( Hotta et al 2007 ) . Addition new biological agent standard chemotherapy regimen may improve outcome patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm metastatic ( stage IV ) NSCLC Measurable disease accord RECIST v.1.0 2009 KRAS , BRAF PI3K wild type primary tumor metastatic tissue . Age ≥18 PS &lt; 2 Adequate organ function Haematology : Neutrophil count ≥1.5x10^9/L Platelet count ≥100x10^9/L Leucocyte count &gt; 3,000/mm Hepatic function : Total bilirubin ≤ 1.5 time upper normal limit ( UNL ) Serum transaminases ≤ 2.5xUNL absence liver metastasis , ≤ 5xUNL presence liver metastases Renal Function : Creatinine clearance ≥ 50 mL/min serum creatinine ≤ 1.5xUNL Metabolic function : Magnesium ≥ low limit normal . Calcium ≥ low limit normal . Consent translational research study Written inform consent Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrollment/randomization , active severe infection concurrent disease . Known CNS metastasis ( pretreatment routine assessment require ) Prior chemotherapy metastatic disease Indication radiation therapy prior radiotherapy within 30 day treatment start . Other malignant disease within 5 year prior inclusion study , except basal cell squamous carcinoma skin cervical carcinomainsitu . Other experimental therapy within 30 day prior treatment initiation . History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . Patients pregnant breast feeding , plan become pregnant within 6 month end treatment . Patients ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Triple mutational status</keyword>
	<keyword>KRAS</keyword>
	<keyword>BRAF</keyword>
	<keyword>PI3K</keyword>
</DOC>